ARA-290: Complete Guide
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B surface of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR) — a heterodimer of EPO receptor and β common receptor — without activating the classical EPO receptor responsible for red blood cell production. This provides tissue-protective and anti-inflammatory effects without the erythropoietic side effects of EPO.
Last updated: 2026-01-29
Quick Facts
- Category
- therapeutic
- Also Known As
- Cibinetide
- Related Goals
- healing, inflammation
Who Researches ARA-290?
ARA-290 is researched by people interested in tissue repair and neuropathic pain without the blood-thickening effects of erythropoietin. It's relevant for researchers studying the EPO tissue-protective pathway, those investigating neuropathy treatments (diabetic, sarcoidosis-related), and anyone exploring tissue repair through innate immune mechanisms. Its separation of tissue-protective from erythropoietic signaling is a conceptually important advance in EPO-derived therapeutics.
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
What Is ARA-290?
Erythropoietin (EPO) is known primarily for stimulating red blood cell production. However, researchers discovered that EPO also has potent tissue-protective effects — preventing cell death, reducing inflammation, and promoting repair in multiple tissues including the brain, heart, and nerves. The problem is that these benefits come packaged with dangerous erythropoietic side effects (blood thickening, thrombosis).
ARA-290 was designed to capture EPO's tissue-protective effects without its blood-stimulating activity. It corresponds to a region on the surface of EPO's helix B that interacts with the innate repair receptor (IRR) — a distinct receptor from the classical EPO receptor responsible for erythropoiesis.
Mechanism of Action
ARA-290 activates the innate repair receptor (IRR), triggering:
- Anti-apoptotic signaling: Activates JAK2/STAT3 and PI3K/Akt pathways in stressed cells, preventing programmed cell death
- Anti-inflammatory effects: Modulates macrophage and monocyte activation, reducing pro-inflammatory cytokine release
- Nerve repair: Promotes small fiber nerve regeneration — particularly relevant for neuropathy
- Tissue repair: Enhances endogenous repair mechanisms without promoting cell proliferation
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
Dosage Overview
Clinical trial dosing: 2–4 mg subcutaneous injection daily or three times weekly. Phase 2 trials in sarcoidosis neuropathy used 2 mg SC three times weekly for 28 days. ARA-290 has a half-life of approximately 2 minutes in plasma, but tissue-level effects persist much longer through downstream signaling cascades.
Side Effects & Safety
- Well-tolerated in clinical trials: No serious drug-related adverse events reported in Phase 1/2 studies
- No erythropoietic effects: Does not increase red blood cell production, hematocrit, or thrombosis risk
- Injection site reactions: Mild and transient
- Headache: Occasionally reported